Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19: Transfer of SARS-CoV-2 antibodies in breast milk
2021-000893-27Phase 4Completed
- Sponsor
- AZ Sint-Jan Brugge
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of davunetide and elasomeran in coronavirus disease 2019 (COVID-19), sponsored by AZ Sint-Jan Brugge. Primary endpoint: Presence and amount of SARS-CoV-2 specific IgM, IgG, and IgA antibodies. Started Mar 2021; status: completed.
02
Drugs
davunetideelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000893-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000893-27.